Italia markets closed

Dow Jones
39.832,00
+273,89(+0,69%)
Nasdaq
16.727,40
+216,22(+1,31%)
Nikkei 225
38.385,73
+29,67(+0,08%)
EUR/USD
1,0879
+0,0058(+0,53%)
Bitcoin EUR
60.117,35
+3.807,22(+6,76%)
CMC Crypto 200
1.376,02
+108,07(+8,53%)

NVCR Dec 2024 20.000 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

3,2400

-0,6100

(-15,84%)

In data: 11:13AM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in